Skip to main content
Premium Trial:

Request an Annual Quote

Bruker AXS Earns Additional $8M as Underwriters Exercise Over-Allotment Option

NEW YORK, Jan. 9 - Bruker AXS on Wednesday said that the underwriters of its initial public offering have exercised their over-allotment option and purchased an additional 1.35 million shares of common stock at $6.50 per share.

 

The action yields the X-ray systems developer roughly $8 million. The purchase also brings Bruker's IPO to 10.35 million shares with a market cap of approximately $62 million.

 

Bruker AXS last month earned $53 million after an IPO let loose 9 million shares of common stock at $6.50 apiece.

 

The two main underwriters were UBS Warburg and Thomas Weisel Partners. CIBC World Markets, SG Cowen, and Robert W. Baird & Co. were co-managers.

 

Bruker AXS develops and sells advanced systems for crystallography, X-ray diffraction, and X-ray fluorescence. It has development partnerships with GeneFormatics and an equity stake in Integrative Proteomics, and acquired the X-ray crystallography division of Delft Instruments in March.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.